Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$9.12 USD
-0.02 (-0.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.13 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
TBPH 9.12 -0.02(-0.22%)
Will TBPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TBPH
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
Other News for TBPH
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Theravance Biopharma Breaks Above 200-Day Moving Average - Bullish for TBPH
Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers
Theravance Biopharma initiated with bullish view at BTIG, here's why
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024